Status:
NOT_YET_RECRUITING
EMPOWER Early Feasibility Study: Non-invasive BCI to Control a Wheelchair for People With Paralysis
Lead Sponsor:
Synaptrix Labs Inc.
Conditions:
Neurologic Disorder
Paralysis
Eligibility:
All Genders
21-75 years
Phase:
NA
Brief Summary
Neuralis is an innovative assistive technology designed for individuals with severe neuromuscular conditions, enabling wheelchair control through EEG signals. This study aims to assess the safety, fea...
Detailed Description
Neuralis, developed by Synaptrix Labs, is an innovative assistive technology engineered to restore mobility and independence for individuals grappling with severe neuromuscular conditions. This cuttin...
Eligibility Criteria
Inclusion
- Severe quadriparesis
- Able to give consent
- Appropriate candidate for device
- Able and willing to access all clinical testing and not impeded by geographical location
- Proficient in English
- Have a study partner
Exclusion
- History of seizures
- History of epilepsy
- Psychiatric or psychological disorder
- No study partner or caregiver
- Unable to provide evidence of COVID vaccination
Key Trial Info
Start Date :
November 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2025
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT06169696
Start Date
November 1 2024
End Date
January 1 2025
Last Update
January 18 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Synaptrix Labs
New York, New York, United States, 10010